Trial reportBMC complementary medicine and therapies2024
Effects of Spirulina supplementation in patients with ulcerative colitis: a double-blind, placebo-controlled randomized trial.
Trial report in BMC complementary medicine and therapies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07609810 (The Effect of Palmitoylethanolamide on the Clinical Outcomes in Ulcerative Colitis Patients), which is not on this map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Palmitoylethanolamide on the Clinical Outcomes in Ulcerative Colitis Patients
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Efficacy and safety of dietary supplements for the treatment of ulcerative colitis, a network meta-analysis.Frontiers in medicine · 2026Pooled it
- Assessing the impact of Spirulina supplementation on the growth of children and adolescents: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Natural antioxidant substances improve oxidative stress and alleviate ulcerative colitis: a meta-analysis of randomized controlled trials.Scientific reports · 2025Pooled it
- Spirulina supplementation and rheumatoid arthritis: A systematic review of current research and molecular mechanisms.Molecular biology reports · 2025Pooled it
- Trial
- Functional Foods and Micro- and Nanoplastics: Advances in Precision Nutritional Medicine for Oral-Gut-Brain Axis Health.Antioxidants (Basel, Switzerland) · 2026Review
- Integrated effects of dietary supplementation of Spirulina platensis in working dogs: nutritional, biochemical, antioxidant, immunological, gut-related microbial and nutrigenomic insights.BMC veterinary research · 2026Article
- Spirulina as a sustainable functional ingredient: nutrient density, bioactives, and food applications.Frontiers in nutrition · 2026Review
- A systematic longitudinal study of microbiome: integrating temporal-spatial dimensions with causal and deep learning models.BMC genomics · 2025Article
- Preclinical and Limited Clinical Evidence for Spirulina in Ulcerative Colitis: A Systematic Review and Meta-analysis.Advanced pharmaceutical bulletin · 2025Review
- Effects of spirulina supplementation on body composition in adults: a GRADE-assessed and dose-response meta-analysis of RCTs.Nutrition & metabolism · 2025Review
- Article
- Antioxidant Therapy in Inflammatory Bowel Diseases: How Far Have We Come and How Close Are We?Antioxidants (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe conducted a randomized placebo-controlled trial to assess the efficacy of Spirulina (SP) supplementation on disease activity, health-related quality of life, antioxidant status, and serum pentraxin 3 (PTX-3) levels in patients with ulcerative colitis (UC).
methodsEighty patients with UC were randomly assigned to consume either 1 g/day (two 500 mg capsules/day) of SP (n = 40) or control (n = 40) for 8 weeks. Dietary intakes, physical activity, disease activity, health-related quality of life, antioxidant status, erythrocyte sedimentation rate (ESR), and serum PTX-3 levels were assessed and compared between groups at baseline and post-intervention.
resultsSeventy-three patients (91.3%) completed the trial. We observed increases in serum total antioxidant capacity levels in the SP supplementation group compared to the control group after 8 weeks of intervention (p ≤ 0.001). A within-group comparison indicated a trend towards a higher health-related quality of life score after 8 weeks of taking two different supplements, SP (p < 0.001) and PL (p = 0.012), respectively. However, there were no significant changes in participant's disease activity score in response to SP administration (p > 0.05). Similarly, changes in ESR and PTX-3 levels were comparable between groups post-intervention (p > 0.05).
conclusionsSP improved antioxidant capacity status and health-related quality of life in patients with UC. Our findings suggest that SP supplementation may be effective as an adjuvant treatment for managing patients with UC. Larger trials with longer interventions periods are required to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.